2 research outputs found
MTâ102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia
Background:
Cachexia, a common manifestation of malignant cancer, is associated with wasting of skeletal muscle and fat tissue. In this study, we investigated the effects of a new first in class anabolic catabolic transforming agent on skeletal muscle in a rat model of cancer cachexia.
Methods:
Young male Wistar Han rats were intraperitoneally inoculated with 108 Yoshida hepatoma AH-130 cells and once daily treated with 0.3 mg kgâ1, 3 mg kgâ1 MT-102, or placebo by gavage.
Results:
Three mg kgâ1dâ1 MT-102 not only prevented progressive loss of fat mass (â6 ± 2 g vs -12 ± 1 g; P < 0.001); lean mass (+1 ± 10 g vs. â37 ± 2 g; P < 0.001) and body weight (+1 ± 13 g vs. â60 ± 2 g; P < 0.001) were remained. Quality of life was also improved as indicated by a higher food intake 12.9 ± 3.1 g and 4.3 ± 0.5 g, 3 mg kgâ1dâ1 MT-102 vs. placebo, respectively, P < 0.001) and a higher spontaneous activity (52 369 ± 6521 counts/24 h and 29 509 ± 1775 counts/24 h, 3 mg·kg-1d-1 MT-102 vs. placebo, respectively, P < 0.01) on Day 11. Most importantly, survival was improved (HR = 0.29; 95% CI: 0.16â0.51, P < 0.001). The molecular mechanisms behind these effects involve reduction of overall protein degradation and activation of protein synthesis, assessed by measurement of proteasome and caspase-6 activity or Western blot analysis, respectively.
Conclusions:
The present study shows that 3 mg kgâ1 MT-102 reduces catabolism, while inducing anabolism in skeletal muscle leading to an improved survival
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
Sarcopenia, the age-related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited